Generics

PISCATAWAY, N.J. — A company focused on developing niche generic and specialty pharmaceutical products has received regulatory approval from the Food and Drug Administration for its version of a psychiatric drug.

Innopharma said its abbreviated new drug application for olanzapine injection, a generic equivalent of Zyprexa injection. With this approval, Innopharma announced that it has entered an agreement with Sandoz, who will sell, market and distribute Innopharma's generic in the United States.

PITTSBURGH — Generic drug maker Mylan's board of directors has approved a new management structure for the company, effective Jan. 1, 2012.

Mylan's board approved the transition of current chairman and CEO Robert Coury to the new role of executive board chairman. With this, Mylan president Heather Bresch will become CEO and directly report to the company's board.

CAMP HILL, Pa. — Medicare Part D beneficiaries will be able to obtain hundreds of generic drugs without any deductible or co-pay under a new program offered by Rite Aid.

The retail pharmacy chain announced Tuesday that it had partnered with Envision Insurance Co. to offer a value-focused prescription drug plan for Medicare Part D Open Enrollment 2012. Rite Aid EnvisionRx Plus offers beneficiaries a plan with a $0 deductible and $0 co-pays, including during the coverage gap, also known as the donut hole.

PHILADELPHIA — Lannett has received approval from the Food and Drug Administration to market its version of an anti-obesity drug.

The FDA approved Lannett's abbreviated new drug application for diethylpropion hydrochloride extended-release tablets in the 75-mg strength. The company expects to begin shipping the product immediately.

WASHINGTON — The Federal Trade Commission released a report Tuesday finding that drug companies entered 28 deals that the FTC called anticompetitive and said would increase healthcare costs for consumers and the government.

The FTC, which under the leadership of chairman Jon Leibowitz, repeatedly has attacked what it calls "pay-for-delay" deals between branded and generic drug manufacturers and has been lobbying the Congressional Joint Select Committee on Deficit Reduction, also known as the super committee, to ban the deals.

HYDERABAD, India — Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

The Indian generic drug maker said the second-quarter sales represented a 21% increase over second quarter 2011. Sales from global generics were $329 million for the quarter, an 18% increase over second quarter 2011, driven mostly by growth in North America and Russia.

Profits for the quarter were $63 million, a 7% increase over second quarter 2011.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic versions of two drugs made by Eli Lilly for treating schizophrenia and bipolar disorder, the agency said Monday.

The FDA announced the approval of generic olanzapine tablets and olanzapine orally disintegrating tablets, respectively generic versions of Lilly's Zyprexa and Zyprexa Zydus. Dr. Reddy's Labs and Teva Pharmaceuticals USA will manufacture olanzapine tablets, while Dr. Reddy's, Apotex and Par Pharmaceuticals will manufacture the orally disintegrating version.

BOSTON — This year’s jump in measles in the United States and Canada was costly and occurred among unvaccinated children and adults, suggested several studies being presented at the 49th Annual Meeting of the Infectious Diseases Society of America here Thursday.